 SAN DIEGO, Oct. 12, 2021 GLOBE NEWSWIRE -- AXIM Biotechnologies, Inc OTCQB: AXIM AXIM Biotech, AXIM or the Company, an international healthcare solutions company targeting oncological, COVID-19 and dry eye disease DED diagnostics, today announced the development of the second generation version of its Rapid Neutralizing Antibody Test for COVID-19. 